Company Revenue

One-time events and competitive pressures created a slower start to 2025 for J&J MedTech's orthopedic sales....

The company grew in the high single digits in 2024 as it made significant progress integrating its Lima acquisition....

The company grew nearly 27% in 2024 as its technology and procedural approach continued to compel surgeon adoption in the...

The company grew in the high single digits in 2024 and made moves to prioritize its most profitable growth opportunities...

The company's 12-Point Plan is producing results, but China will remain a major drag on sales and profitability in 2025....

The company grew in the mid-single-digits in the fourth quarter of 2024 and set records for its enabling technology sales...

The company's orthopedic sales grew in the mid-single-digits for calendar year 2024 as its enabling technology disrupts market dynamics....

The company grew 3.8% in 2024 driven by better operational performance and strategic efforts to enter higher-growth markets....

The company's orthopedic sales grew below-market at 2% in 2024 as it worked through significant supply chain challenges....

The company's orthopedic sales grew in the high single digits in 2024, driven by new products and healthy procedure demand....